Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Advances in PARP inhibitor use for metastatic breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.19
Views: 3348

Prof Hope Rugo - University of California, San Francisco, USA

Prof Hope Rugo speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the recent advances in the use of PARP inhibitors for the treatment of metastatic breast cancer.

She describes where we are currently with PARP inhibitor use for this type of cancer and notes that patient quality of life is improved with this targeted therapy compared to conventional chemotherapy.

Prof Rugo states that new research is focusing on assessing the effectiveness of these drugs in somatic and other DNA damaging mutations.

She also discusses the toxicities that are associated with the use of this drug and emphasises that discontinuation rates are low among this patient population.

Prf Rugo mentions data from the OLYMPIAD trial, which showed a clinically significant survival benefit in the first-line setting for olaparib and remarkable complete response rates from the neo-adjuvant administration of talazoparib.

Over the next few years, Prof Rugo anticipates that PARP inhibitors will play an important role in the neoadjuvant setting for residual disease and the possible use of these inhibitors as a monotherapy in a subset of patients.

This programme has been supported by an unrestricted educational grant from Pfizer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation